期刊
CEPHALALGIA
卷 37, 期 4, 页码 391-395出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102416644435
关键词
Migraine; headache; pituitary adenylate cyclase-activating polypeptide-38; experimental migraine model; dose-response
资金
- Novo Nordisk Foundation [NNF11OC1014333]
- Independent Research-Medical Sciences (FSS) [DFF-1331-00210A]
- Lundbeck Foundation [R155-2014-171]
- FP7-EUROHEADPAIN [602633]
- Danish Neurological Society
- Lundbeck Foundation [R155-2014-171] Funding Source: researchfish
Background: Intravenous infusion of 10 pmol/kg/min pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces migraine-like attacks in migraine patients without aura (MO). Here, we conducted a pilot study and investigated if lower doses of PACAP38 exert similar migraine-inducing abilities. Methods: We randomly allocated six MO patients to receive intravenous infusion of 4, 6, and 8 pmol/kg/min of PACAP38 over 20 minutes in a double-blind, three-way cross-over study. Headache and migraine characteristics were recorded during hospital (0-2 hours) and post-hospital (2-13 hours) phases. Results: PACAP38 induced migraine-like attacks in one out of six patients with 4 pmol, two out of six patients with 6 pmol and three out of six patients with 8 pmol (p = 0.368). All patients reported head pain after 8 pmol/kg/min, whereas five of six participants reported head pain after both 4 and 6 pmol/kg/min. We found no difference between the three doses in the AUC for headache intensity over the 12-hour observation period (p = 0.142). An exploratory analysis showed a significant difference between 4 pmol and 8 pmol (p = 0.031). Conclusion: A trend of a dose-response relationship between dose of PACAP38 and incidence of migraine was observed. We suggest that 10 pmol/kg/min PACAP38 is the most optimal dose to induce migraine-like attacks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据